-
Product Insights
NewLikelihood of Approval Analysis for Mesenchymal Tumor Of The Gastrointestinal Tract
Overview How likely is it that the drugs in Mesenchymal Tumor Of The Gastrointestinal Tract will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesenchymal Tumor Of The Gastrointestinal Tract Overview Mesenchymal...
-
Product Insights
NewLikelihood of Approval Analysis for Carcinoid Tumor
Overview How likely is it that the drugs in Carcinoid Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carcinoid Tumor Overview Carcinoid tumors are slow-growing tumors arising from neuroendocrine cells...
-
Product Insights
NewLikelihood of Approval Analysis for Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Overview How likely is it that the drugs in Clostridioides difficile Infections (Clostridium difficile Associated Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Clostridioides difficile Infections (Clostridium difficile Associated Disease)...
-
Sector Analysis
NewAzerbaijan Insurance Industry – Key Trends and Opportunities to 2028
Azerbaijan Insurance Market Report Overview The gross written premium (GWP) of the Azerbaijan insurance market was AZN1.2 billion ($719.1 million) in 2023. The market will achieve a CAGR of more than 6% during 2024-2028. The Azerbaijan insurance market research report provides in-depth market analysis, information, and insights into the Azerbaijan insurance industry. It provides a detailed outlook by product category as well as values for key performance indicators such as gross written premium, penetration, premium accepted and ceded, profitability ratios,...
-
Sector Analysis
NewKenya General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
Kenya General Insurance Market Report Overview The gross written premium of the Kenya general insurance market was KES188 billion ($1.3 billion) in 2023 and will achieve a CAGR of more than 9% during 2024-2028. The Kenya general insurance market research report provides in-depth market analysis, including insights into the lines of business in the country’s general insurance industry. Furthermore, the report provides a detailed outlook by product category as well as values for key performance indicators, including gross written premium,...
-
Sector Analysis
Germany General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
Germany General Insurance Market Report Overview The gross written premium of the German general insurance market was EUR159.5 billion ($162.9 billion) in 2023 and is expected to achieve a CAGR of more than 5% during 2024-2028. The Germany general insurance market research report provides a detailed outlook by product category for Germany’s general insurance segment. Germany General Insurance Market Outlook, 2023-2028 (EUR Billion) Buy the Full Report to Gain More Information about the Germany General Insurance Market Forecast Download a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VXAG-1.1NN in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VXAG-1.1NN in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VXAG-1.1NN in Norovirus Infections Drug Details: VXAG-1.1NN is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-1200 in Gastrointestinal Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-1200 in Gastrointestinal Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-1200 in Gastrointestinal Tumor Drug Details: MK-1200 is under development for the...
-
Product Insights
NewNet Present Value Model: Vaxart Inc’s Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Empower your strategies with our Net Present Value Model: Vaxart Inc's Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GI-6301 in Chordoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GI-6301 in Chordoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GI-6301 in Chordoma Drug Details: GI-6301 is under development for the treatment...